These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 25324139)
1. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer. Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061 [TBL] [Abstract][Full Text] [Related]
4. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. Abuzeid WM; Jiang X; Shi G; Wang H; Paulson D; Araki K; Jungreis D; Carney J; O'Malley BW; Li D J Clin Invest; 2009 Jul; 119(7):1974-85. PubMed ID: 19487811 [TBL] [Abstract][Full Text] [Related]
5. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. Zhong ZH; Jiang WQ; Cesare AJ; Neumann AA; Wadhwa R; Reddel RR J Biol Chem; 2007 Oct; 282(40):29314-22. PubMed ID: 17693401 [TBL] [Abstract][Full Text] [Related]
6. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991 [TBL] [Abstract][Full Text] [Related]
7. Targeting Rad50 sensitizes human nasopharyngeal carcinoma cells to radiotherapy. Chang L; Huang J; Wang K; Li J; Yan R; Zhu L; Ye J; Wu X; Zhuang S; Li D; Zhang G BMC Cancer; 2016 Mar; 16():190. PubMed ID: 26951044 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Clark CC; Weitzel JN; O'Connor TR Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma. Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007 [TBL] [Abstract][Full Text] [Related]
10. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085 [TBL] [Abstract][Full Text] [Related]
11. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. Chen L; Nievera CJ; Lee AY; Wu X J Biol Chem; 2008 Mar; 283(12):7713-20. PubMed ID: 18171670 [TBL] [Abstract][Full Text] [Related]
12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
13. PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex. Qiu L; Li R; Wang Y; Lu Z; Tu Z; Liu H Br J Cancer; 2024 Aug; 131(3):577-588. PubMed ID: 38866962 [TBL] [Abstract][Full Text] [Related]
14. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
15. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619 [TBL] [Abstract][Full Text] [Related]
16. The involvement of the Mre11/Rad50/Nbs1 complex in the generation of G-overhangs at human telomeres. Chai W; Sfeir AJ; Hoshiyama H; Shay JW; Wright WE EMBO Rep; 2006 Feb; 7(2):225-30. PubMed ID: 16374507 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Hsu HM; Wang HC; Chen ST; Hsu GC; Shen CY; Yu JC Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2024-32. PubMed ID: 17932350 [TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. Moutafi M; Economopoulou P; Rimm D; Psyrri A Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558 [TBL] [Abstract][Full Text] [Related]